Previous 10 | Next 10 |
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced acceptance of an abstract for KVD900 as an oral presentation at the 12 th C1-Inh...
KalVista Pharmaceuticals (KALV) appointed 20-years industry veteran Paul K. Audhya, MD, MBA, as Chief Medical Officer."Paul is joining at the perfect time to apply his expertise in global medical affairs, drug development and international product launches as we evolve into a commercial ...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today the appointment of Paul K. Audhya, MD, MBA, as Chief Medical Officer. This press...
Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...
The FDA has notified KalVista Pharmaceuticals (KALV) that it has placed a clinical hold on the proposed Phase 2 clinical trial of KVD824. An Investigational New Drug Application was submitted earlier for a Phase 2 trial to evaluate KVD824 as a potential prophylactic treatment for the pre...
– KVD824 Phase 2 on Clinical Hold – – Planning for KVD900 Phase 3 Unaffected – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small mol...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2...
KalVista Pharmaceticals (KALV): FQ3 GAAP EPS of -$0.56 beats by $0.04.Cash, cash equivalents and marketable securities were $50.3MPress Release For further details see: KalVista Pharmaceticals EPS beats by $0.04
– Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant – – IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 – – Following Upsized Public Offer...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the 10 th Annual SVB Leerink Global He...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...